Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2

Paolo Lissoni, Mario Mandalà, Giuseppe Curigliano, Gianluigi Ferretti, Cecilia Moro, Antonio Ardizzoia, Fabio Malugani, Gabriele Tancini, Elisabetta Tisi, Carlo Arrigoni, Sandro Barni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: Several cytokines, particularly IL-2 and interferons, are thought to be effective in the palliative therapy of neoplastic effusions. We report on the activity and toxicity of intracavitary administration of low-dose IL-2 in a case series of 100 cancer patients with neoplastic effusions. Methods: One hundred patients with advanced solid tumors and neoplastic effusions underwent IL-2 intracavitary injection as first-line treatment. The most common sites of fluid accumulation were pleura (n = 68), peritoneum (n = 21) and pericardium (n = 11). Breast cancer, lung cancer and mesothelioma were the most frequent neoplasms in our series. One cycle consisted of intracavitary IL-2 at 6,000,000 IU on days 1 and 7. Results: According to Paladine's criteria, an objective clinical response was achieved in 72% (complete response in 27% and partial response in 45%), with a median duration of 5 months (range: 1-11 months). The peritoneum was the least responsive site for neoplastic effusion reduction. IL-2 intracavitary injection was well tolerated in all patients; the only toxicity observed was fever >38°C in 6% of the patients. Conclusion: This study shows that intracavitary injection of IL-2 represents a feasible, well-tolerated and effective therapy of neoplastic fluid accumulation. Further studies are needed in order to compare the effectiveness of intracavitary IL-2 with other standard treatments.

Original languageEnglish
Pages (from-to)308-312
Number of pages5
JournalOncology
Volume60
Issue number4
DOIs
Publication statusPublished - 2001

Fingerprint

Palliative Care
Interleukin-2
Peritoneum
Injections
Lung Neoplasms
Neoplasms
Pleura
Fluid Therapy
Pericardium
Mesothelioma
Interferons
Fever
Breast Neoplasms
Cytokines
Therapeutics

Keywords

  • Interleukin-2
  • Intracavitary therapy
  • Neoplastic effusions
  • Palliative treatment

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. / Lissoni, Paolo; Mandalà, Mario; Curigliano, Giuseppe; Ferretti, Gianluigi; Moro, Cecilia; Ardizzoia, Antonio; Malugani, Fabio; Tancini, Gabriele; Tisi, Elisabetta; Arrigoni, Carlo; Barni, Sandro.

In: Oncology, Vol. 60, No. 4, 2001, p. 308-312.

Research output: Contribution to journalArticle

Lissoni, P, Mandalà, M, Curigliano, G, Ferretti, G, Moro, C, Ardizzoia, A, Malugani, F, Tancini, G, Tisi, E, Arrigoni, C & Barni, S 2001, 'Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2', Oncology, vol. 60, no. 4, pp. 308-312. https://doi.org/10.1159/000058525
Lissoni, Paolo ; Mandalà, Mario ; Curigliano, Giuseppe ; Ferretti, Gianluigi ; Moro, Cecilia ; Ardizzoia, Antonio ; Malugani, Fabio ; Tancini, Gabriele ; Tisi, Elisabetta ; Arrigoni, Carlo ; Barni, Sandro. / Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. In: Oncology. 2001 ; Vol. 60, No. 4. pp. 308-312.
@article{74008c970c9c4a9b86f84d546db1aea0,
title = "Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2",
abstract = "Objective: Several cytokines, particularly IL-2 and interferons, are thought to be effective in the palliative therapy of neoplastic effusions. We report on the activity and toxicity of intracavitary administration of low-dose IL-2 in a case series of 100 cancer patients with neoplastic effusions. Methods: One hundred patients with advanced solid tumors and neoplastic effusions underwent IL-2 intracavitary injection as first-line treatment. The most common sites of fluid accumulation were pleura (n = 68), peritoneum (n = 21) and pericardium (n = 11). Breast cancer, lung cancer and mesothelioma were the most frequent neoplasms in our series. One cycle consisted of intracavitary IL-2 at 6,000,000 IU on days 1 and 7. Results: According to Paladine's criteria, an objective clinical response was achieved in 72{\%} (complete response in 27{\%} and partial response in 45{\%}), with a median duration of 5 months (range: 1-11 months). The peritoneum was the least responsive site for neoplastic effusion reduction. IL-2 intracavitary injection was well tolerated in all patients; the only toxicity observed was fever >38°C in 6{\%} of the patients. Conclusion: This study shows that intracavitary injection of IL-2 represents a feasible, well-tolerated and effective therapy of neoplastic fluid accumulation. Further studies are needed in order to compare the effectiveness of intracavitary IL-2 with other standard treatments.",
keywords = "Interleukin-2, Intracavitary therapy, Neoplastic effusions, Palliative treatment",
author = "Paolo Lissoni and Mario Mandal{\`a} and Giuseppe Curigliano and Gianluigi Ferretti and Cecilia Moro and Antonio Ardizzoia and Fabio Malugani and Gabriele Tancini and Elisabetta Tisi and Carlo Arrigoni and Sandro Barni",
year = "2001",
doi = "10.1159/000058525",
language = "English",
volume = "60",
pages = "308--312",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2

AU - Lissoni, Paolo

AU - Mandalà, Mario

AU - Curigliano, Giuseppe

AU - Ferretti, Gianluigi

AU - Moro, Cecilia

AU - Ardizzoia, Antonio

AU - Malugani, Fabio

AU - Tancini, Gabriele

AU - Tisi, Elisabetta

AU - Arrigoni, Carlo

AU - Barni, Sandro

PY - 2001

Y1 - 2001

N2 - Objective: Several cytokines, particularly IL-2 and interferons, are thought to be effective in the palliative therapy of neoplastic effusions. We report on the activity and toxicity of intracavitary administration of low-dose IL-2 in a case series of 100 cancer patients with neoplastic effusions. Methods: One hundred patients with advanced solid tumors and neoplastic effusions underwent IL-2 intracavitary injection as first-line treatment. The most common sites of fluid accumulation were pleura (n = 68), peritoneum (n = 21) and pericardium (n = 11). Breast cancer, lung cancer and mesothelioma were the most frequent neoplasms in our series. One cycle consisted of intracavitary IL-2 at 6,000,000 IU on days 1 and 7. Results: According to Paladine's criteria, an objective clinical response was achieved in 72% (complete response in 27% and partial response in 45%), with a median duration of 5 months (range: 1-11 months). The peritoneum was the least responsive site for neoplastic effusion reduction. IL-2 intracavitary injection was well tolerated in all patients; the only toxicity observed was fever >38°C in 6% of the patients. Conclusion: This study shows that intracavitary injection of IL-2 represents a feasible, well-tolerated and effective therapy of neoplastic fluid accumulation. Further studies are needed in order to compare the effectiveness of intracavitary IL-2 with other standard treatments.

AB - Objective: Several cytokines, particularly IL-2 and interferons, are thought to be effective in the palliative therapy of neoplastic effusions. We report on the activity and toxicity of intracavitary administration of low-dose IL-2 in a case series of 100 cancer patients with neoplastic effusions. Methods: One hundred patients with advanced solid tumors and neoplastic effusions underwent IL-2 intracavitary injection as first-line treatment. The most common sites of fluid accumulation were pleura (n = 68), peritoneum (n = 21) and pericardium (n = 11). Breast cancer, lung cancer and mesothelioma were the most frequent neoplasms in our series. One cycle consisted of intracavitary IL-2 at 6,000,000 IU on days 1 and 7. Results: According to Paladine's criteria, an objective clinical response was achieved in 72% (complete response in 27% and partial response in 45%), with a median duration of 5 months (range: 1-11 months). The peritoneum was the least responsive site for neoplastic effusion reduction. IL-2 intracavitary injection was well tolerated in all patients; the only toxicity observed was fever >38°C in 6% of the patients. Conclusion: This study shows that intracavitary injection of IL-2 represents a feasible, well-tolerated and effective therapy of neoplastic fluid accumulation. Further studies are needed in order to compare the effectiveness of intracavitary IL-2 with other standard treatments.

KW - Interleukin-2

KW - Intracavitary therapy

KW - Neoplastic effusions

KW - Palliative treatment

UR - http://www.scopus.com/inward/record.url?scp=17844380760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844380760&partnerID=8YFLogxK

U2 - 10.1159/000058525

DO - 10.1159/000058525

M3 - Article

C2 - 11408797

AN - SCOPUS:17844380760

VL - 60

SP - 308

EP - 312

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -